Business
Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights
Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption (IDE) approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025 Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercializat
About this update from Glucotrack, Inc.
[{"type":"image","alt":"GlucoTrack, Inc.","displaySize":"","headline":null,"caption":"GlucoTrack, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/34ddda24ce1daf5f60ba6f7c2be22d4a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jLjmYeICxeIiiA5nYSpJ3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/34ddda24ce1daf5f60ba6f7c2be22d4a","width":300,"height":64}},"lazy":false},{"type":"text","content":"Transformational 2024: successfully advanced from preclinical to clinical stage company","length":87,"tagName":"p"},{"type":"text","content":"Strengthened leadership team to drive growth and advance clinical development","length":77,"tagName":"p"},{"type":"text","content":"Investigational Device Exemption (IDE) approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025","length":134,"tagName":"p"},{"type":"text","content":"Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2024.","length":377,"tagName":"p"},{"type":"text","content":"“2024 was transformative for Glucotrack as we advanced the development of our CBGM technology and successfully transitioned from a preclinical to a clinical stage company. As we move into the next phase of growth, we have also strengthened our leadership team with key additions to our senior leadership, clinical and regulatory management team as well as our Medical Advisory Board,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “We are confident that our differentiated technology for blood glucose monitoring will change the lives of those living with diabetes and improve patient outcomes. This will be the first fully implantable CBGM technology with a multi-year monitoring system and real-time measuring capabilities, offering differentiated benefits of accuracy, convenience and independence for patients.”","length":847,"tagName":"p"},{"type":"text","content":"Dr. Goode continued, “As we look to 2025, I am p...